A Randomized, Double-blind, Two-group Parallel, Positive-controlled Clinical Phase I Trial Comparing the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet Age-related Macular Degeneration.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2019
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
- 10 Apr 2019 Status changed from recruiting to completed.
- 24 Oct 2017 New trial record